NEW YORK, Nov. 5, 2019 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today that its technology partner, Mannin, has received a $7.5M grant from the German state of Saxony. Mannin is a research-stage biotechnology company focused on the discovery, development, and commercialization of therapeutics for vascular diseases. It was founded in July 2012 and is led by President and CEO, Dr. George Nikopoulos. Q BioMed and Mannin have been partners since 2015.
The overall objective of the grant is to fund the development of novel pharmaceuticals and biologic treatments for glaucoma. There have been few innovations in glaucoma drug development in recent history and glaucoma remains a leading cause of blindness in Europe. More innovation and solutions are required to address the unmet needs of more than 12 million Europeans who suffer from this disease.
The approval of the grant means that Q BioMed and Mannin can significantly accelerate the development of these therapeutics. Denis Corin, CEO of Q BioMed, said of the grant, "We are thrilled that we will be able to speed the development of these promising therapeutics and bring new innovation to glaucoma patients as soon as possible. Our partnership with Mannin and now, the government of Saxony is important to the advancement of this unique drug platform and we look forward to supporting the build-out of the Mannin European headquarters in Leipzig."
Mannin is leveraging two distinct modes of action to reduce the intraocular pressure that causes glaucoma, utilizing different routes of administration and dosing regimens. Mannin is currently working on the preclinical development of a small molecule pharmaceutical eye-drop as well as a novel recombinant protein injectable biologic. This approach increases the probability of success of developing a new therapy that is optimized for the needs of glaucoma patients. Additionally, Mannin is exploring other therapeutic opportunities using these molecules for vascular diseases.
George Nikopoulos, President and CEO of Mannin, stated, "We are very encouraged by the confidence and enthusiasm the government of Saxony has shown in our research, and we are committed to making accelerated progress through their investment."
Q BioMed and Mannin intend to announce further details regarding the research program later this year.
About Q BioMed Inc.
Q BioMed Inc. is a biotech acceleration and commercial stage company. We are focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. Q BioMed is dedicated to providing these target assets; strategic resources, developmental support, and expansion capital to ensure they meet their developmental potential, enabling them to provide products to patients in need‏.
Please visit www.qbiomed.com and sign up for regular updates.
Contact:
Denis Corin
CEO
Q BioMed Inc.
+1(646) 884-7017
Investor Relations:
+1(404) 995-6671
This email address is being protected from spambots. You need JavaScript enabled to view it.
About Mannin Research, Inc.
Mannin Research, Inc. is a research-stage biotechnology company focused on the discovery, development, and commercialization of therapeutics for vascular diseases. The lead program is for a first-in-class therapeutic eye drop for the treatment of Primary Open Angle Glaucoma. Mannin is developing a unique molecule in the form of an easy-to-administer eye drop designed to repair the normal flow of fluid in the eye resulting in the reduction of intra-ocular eye pressure (IOP), one of the main causes of Glaucoma. Mannin is the only company targeting this method of action. Mannin has a deep pipeline of novel therapeutics that can be developed from this research platform which would treat a spectrum of vascular diseases including Cystic Kidney Disease, Pediatric Glaucoma, Cardiovascular Disease and Inflammation.
Forward-Looking Statements:
This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.
Media Contact Mannin:
George Nikopoulos
President and CEO
+1-416-306-2853
This email address is being protected from spambots. You need JavaScript enabled to view it.
SOURCE Q BioMed Inc.